Journal Image
Recent Patents on Biomarkers
ISSN (Print): 2210-3090
ISSN (Online): 2210-3104
DOI: 10.2174/2210309011101030213

TWEAK as a Biomarker

Author(s): Ana B. Sanz, Maria C. Izquierdo, Alvaro C. Ucero, Maria D. Sanchez Nino, Jesus Egido and Alberto Ortiz
Pages 213-221 (9)
TWEAK is a cytokine that belongs to the TNF superfamily. TWEAK binds to the Fn14 receptor to activate alternative and classical NFκB pathways, MAPKs, TAK1 and PI3K/Akt intracellular signaling pathways. TWEAK regulates cell proliferation, cell death, cell differentiation, angiogenesis and inflammation. Functional studies targeting TWEAK and/or Fn14 implicate the system in acute and chronic tissue injury, tissue repair and cancer. Circulating soluble TWEAK has been postulated as a biomarker of endothelial injury, atherosclerosis and clinical outcomes in chronic kidney disease patients. In addition, urinary TWEAK has been suggested to be a biomarker of lupus nephritis activity. A database search yielded one patent on TWEAK as a biomarker of subclinical cardiovascular injury. Further research is needed to validate the relevance of TWEAK assessment as a decision-making clinical tool.
Atherosclerosis, biomarker, cardiovascular, chronic kidney disease, lupus nephritis, outcomes, TWEAK, TNF receptor superfamily, MULTIFUNCTIONAL CYTOKINE, Inflammation, Cell proliferation
Unidad de Dialisis Fundacion Jimenez Diaz Av Reyes Catolicos 2, 28040 Madrid, Spain.